Foundayo Tablet Trial Largely Prevents Weight Regain as 50 Obesity Drug Studies Advance
Updated
Updated · BBC.com · May 16
Foundayo Tablet Trial Largely Prevents Weight Regain as 50 Obesity Drug Studies Advance
5 articles · Updated · BBC.com · May 16
Trial results released this month showed Foundayo, a GLP-1 weight-loss tablet, largely avoided the weight regain commonly seen after treatment changes or discontinuation.
That finding targets a key weakness of current GLP-1 drugs, which have helped drive major weight loss but often see patients rapidly regain much of it once they stop.
About 100 million people worldwide are already using GLP-1 medicines, while more than 50 clinical trials are underway for new obesity treatments, according to the report.
In the UK, wider use still faces cost barriers: NICE said 3.4 million people could qualify for Mounjaro under standard criteria, but NHS modelling put annual costs as high as £3.9 billion.
Tablets could broaden access if priced below injections; Wegovy weight-loss tablets are already marketed in the US, and a UK decision is expected later this year.
As oral pills become common, will 'miracle' obesity drugs become a daily routine or remain a luxury item?
After the weight loss jab, will we need another pill just to stop the weight from coming back?
These drugs rewire brain reward circuits. Are we risking our ability to feel pleasure for the sake of being thin?
Foundayo Debuts: How Oral GLP-1 Pills Are Reshaping Obesity Treatment and Global Access
Overview
Eli Lilly has launched Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist, after receiving expedited FDA approval through the Commissioner’s National Priority Voucher program. This program condensed the review process to just 100 days, compared to the traditional timeline that would have delayed approval until 2027. According to Eli Lilly’s CEO, the rapid review was as thorough as usual, only faster. Foundayo is now available in pharmacies and on Lilly Direct, aiming to address the urgent public health challenge of obesity by offering a convenient oral option for weight management.